Latest Articles

Publication Date
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer - Medpage Today

Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer Medpage Today

Published: June 18, 2024, 7 a.m.
FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma - AJMC.com Managed Markets Network

FDA Approves Pembrolizumab With Chemotherapy in Advanced Endometrial Carcinoma AJMC.com Managed Markets Network

Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer - Reuters

AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer Reuters

Published: June 17, 2024, 7 a.m.
In Memory Of Dr. Michael Brodherson - Endometriosis Foundation of America - The Blossom

In Memory Of Dr. Michael Brodherson Endometriosis Foundation of America - The Blossom

Published: June 17, 2024, 7 a.m.
Film screening in Cork aims to highlight the problems in treatment for Endometriosis - EchoLive.ie

Film screening in Cork aims to highlight the problems in treatment for Endometriosis EchoLive.ie

Published: June 14, 2024, 7 a.m.
Adding Immunotherapy to Chemotherapy for Endometrial Cancer - Cleveland Clinic

Adding Immunotherapy to Chemotherapy for Endometrial Cancer Cleveland Clinic

Published: June 13, 2024, 7 a.m.
Lala salama: Njambi's glowing tribute to her uncle, DJ Teknix re-emerges - Tuko.co.ke

Lala salama: Njambi's glowing tribute to her uncle, DJ Teknix re-emerges Tuko.co.ke

Published: June 12, 2024, 7 a.m.
Relugolix combination therapy effective, safe for premenopausal women with endometriosis - Healio

Relugolix combination therapy effective, safe for premenopausal women with endometriosis Healio

Published: June 11, 2024, 7 a.m.
Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer - Cancer Therapy Advisor

Abemaciclib Plus Fulvestrant Demonstrates Activity in Advanced Endometrial Cancer Cancer Therapy Advisor

Published: June 11, 2024, 7 a.m.
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets - The ASCO Post

Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post

Published: June 10, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!